oxalis conorrhiza/παχυσαρκία

Ο σύνδεσμος αποθηκεύεται στο πρόχειρο

Άρθρα Κλινικές δοκιμέςΔιπλώματα ευρεσιτεχνίας

Επιλέξτε τύπο ταξινόμησης

Σελίδα 1 από 24 Αποτελέσματα

Effects of perilipin (PLIN) gene variation on metabolic syndrome risk and weight loss in obese children and adolescents.

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

BACKGROUND Genetic polymorphisms at the perilipin (PLIN) locus have been investigated for their potential utility as markers for obesity and metabolic syndrome (MS). We examined in obese children and adolescents (OCA) aged 7-14 yr the association of single-nucleotide polymorphisms (SNP) at the PLIN

Obeticholic acid ameliorates severity of Clostridioides difficile infection in high fat diet-induced obese mice

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

Severe Clostridiodes difficile infection (CDI) is life-threatening and responds poorly to treatment. Obesity is associated with development of severe CDI. Therefore, to define the mechanisms that exacerbate disease severity, we examined CDI pathogenesis in high-fat diet (HFD)-fed obese mice.

Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice.

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

Nonalcoholic steatohepatitis (NASH) is the outcome of interactions between overnutrition, energy metabolism, and adipose function. Obeticholic acid (OCA) improves steatosis in patients but for unknown reasons does not resolve NASH pathology. This study therefore investigated OCA effects in Wt mice,

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

OBJECTIVE To evaluate the pharmacodynamics of compounds in clinical development for nonalcoholic steatohepatitis (NASH) in obese mouse models of biopsy-confirmed NASH. METHODS Male wild-type C57BL/6J mice (DIO-NASH) and Lep ob/ob (ob/ob-NASH) mice were fed a diet high in trans-fat (40%), fructose

Phenolic compounds rutin and o-coumaric acid ameliorate obesity induced by high-fat diet in rats.

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

Dietary fat is one of the most important environmental factors associated with the incidence of cardiovascular diseases. In this study, the antiobesity effects of rutin (R) and o-coumaric acid (oCA) were investigated. Wistar rats were divided into normal and obese groups, and obese rats were prefed

FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

Bile acids are ligands for the nuclear hormone receptor farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5. We have shown that FXR and TGR5 have renoprotective roles in diabetes- and obesity-related kidney disease. Here, we determined whether these effects are mediated through

HELICOBACTER PYLORI (HP) INFECTION IN OBESE PATIENTS UNDERGOING ROUXEN- Y GASTRIC BYPASS; EFFICACY OF TWO DIFFERENT TREATMENT REGIMENS IN HP ERADICATION.

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

BACKGROUND the ultimate cause for the increased incidence of gastric ulcer following Roux-en-Y gastric bypass (RYGB) remains unclear. Treatment of HP infection is recommended before surgery in countries with high prevalence such as Spain in other to diminish the risk. However, the current regimens

Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

Purpose of review: Nonalcoholic fatty liver disease (NAFLD) has emerged as the leading cause of chronic liver disease in both adults and children. In this article, we review recent developments in the screening, diagnosis, and treatment

Inhibitory effects of Capsicum annuum L. water extracts on lipoprotein lipase activity in 3T3-L1 cells.

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

Obesity, an intractable metabolic disease, currently has no medical treatment without side effects, so studies have been actively carried out to find natural compounds that have anti-obesity activity with minimum side effects. In this study, the anti-obesity effects of water extracts of seven

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

Nonalcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and its prevalence is increasing driven by the pandemic of obesity and type 2 diabetes mellitus. NAFLD can progress to cirrhosis and is associated with increased risk for cardiovascular disease and hepatocellular cancer.

Farnesoid X receptor activation induces the degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver disease.

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

Patients with non-alcoholic fatty liver disease (NAFLD) exhibit higher levels of plasma 1-deoxysphingolipids than healthy individuals. The aim of this study was to investigate the role of farnesoid X receptor (FXR) in 1-deoxysphingolipid de novo synthesis and

Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents.

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases. The bile acid-derived FXR agonist obeticholic acid (OCA) has shown promise in a phase 2 study in patients with nonalcoholic steatohepatitis (NASH). Here, we

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

Cardiometabolic diseases are characterized as a combination of multiple risk factors for cardiovascular disease (CVD) and metabolic diseases including diabetes mellitus and dyslipidemia. Cardiometabolic diseases are closely associated with cell glucose and lipid metabolism, inflammatory response and

A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

Non-alcoholic steatohepatitis (NASH) is a fast-growing liver disorder that is associated with an increased incidence of cardiovascular disease and type 2 diabetes. Animal models adequately mimicking this condition are scarce. We herein investigate whether Ldlr-/-. Leiden mice on different high-fat

Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα

Σύνδεση εγγραφή

Nonalcoholic steatohepatitis (NASH) is an unmet need associated with metabolic syndrome. There are no approved therapies for NASH; however, glucagon-like peptide-1 receptor (GLP-1R) and farnesoid-X receptor (FXR) agonists are promising drug targets. We investigated the therapeutic effects of

Προηγούμενος
1
2
Επόμενο

Γίνετε μέλος της σελίδας
μας στο facebook

Herbal & Natural Medicine

Η πληρέστερη βάση δεδομένων φαρμακευτικών βοτάνων που υποστηρίζεται από την επιστήμη

Λειτουργεί σε 55 γλώσσες
Βοτανικές θεραπείες που υποστηρίζονται από την επιστήμη
Αναγνώριση βοτάνων με εικόνα
Διαδραστικός χάρτης GPS - ετικέτα βότανα στην τοποθεσία (σύντομα)
Διαβάστε επιστημονικές δημοσιεύσεις που σχετίζονται με την αναζήτησή σας
Αναζήτηση φαρμακευτικών βοτάνων με τα αποτελέσματά τους
Οργανώστε τα ενδιαφέροντά σας και μείνετε ενημερωμένοι με την έρευνα ειδήσεων, τις κλινικές δοκιμές και τα διπλώματα ευρεσιτεχνίας

Πληκτρολογήστε ένα σύμπτωμα ή μια ασθένεια και διαβάστε για βότανα που μπορεί να βοηθήσουν, πληκτρολογήστε ένα βότανο και δείτε ασθένειες και συμπτώματα κατά των οποίων χρησιμοποιείται.
* Όλες οι πληροφορίες βασίζονται σε δημοσιευμένη επιστημονική έρευνα